Clinical trial
NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer
NCT05213195 is registered in ClinicalTrials.gov with Zhejiang University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer
- Lead sponsor
- Zhejiang University
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- December 10, 2021
- Completion date
- June 30, 2025
- Enrollment
- 38 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
refractory metastatic colorectal cancer